{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:58:48Z","timestamp":1775473128086,"version":"3.50.1"},"reference-count":20,"publisher":"Medical Association of Zenica-Doboj","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicinski Glasnik"],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:p>&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Aim&amp;lt;\/strong&amp;gt; &amp;lt;br \/&amp;gt;To evaluate Helicobacter pylori (H. pylori) resistance to clarithromycin and quinolones in patients with dyspepsia in Tuzla&amp;lt;br \/&amp;gt;Canton, Bosnia and Herzegovina, a region with no data on clarithromycin or quinolones resistance.&amp;lt;br \/&amp;gt;&amp;lt;strong&amp;gt;Methods&amp;lt;\/strong&amp;gt; &amp;lt;br \/&amp;gt;A prospective cross-sectional study was conducted at the Department of Gastroenterology and Hepatology at University&amp;lt;br \/&amp;gt;Clinical Centre Tuzla between January 2021 and June 2022. The study included 99 patients who underwent esophagogastroduodenoscopy (EGDS) due to dyspepsia. In all patients biopsies were taken for rapid urease test (RUT) and histology findings, concomitantly with blood samples for IgG serology. All RUT positive patient samples were tested for clarithromycin and quinolones susceptibility with GenoType HelicoDr, a PCR method which detects point mutations in 23S rRNA and mutations in the gyrA gene.&amp;lt;br \/&amp;gt;&amp;lt;strong&amp;gt;Results&amp;lt;\/strong&amp;gt; &amp;lt;br \/&amp;gt;Out of 99 dyspeptic patients, 67 (67.7%) were serologically positive to H. pylori, 46 (46.4.%) were RUT positive, and&amp;lt;br \/&amp;gt;19 (19.2 %) had a positive histology finding. Antibiotic (AB) resistance was tested in the total of 46\/99 (46.4%) patients. Resistance to clarithromycin was detected in 28.26% (13\/46), quinolones resistance in 36.96% (17\/46) , and resistance to both AB was detected in 8.69% (4\/46) tested biopsies.&amp;lt;br \/&amp;gt;&amp;lt;strong&amp;gt;Conclusions&amp;lt;\/strong&amp;gt; &amp;lt;br \/&amp;gt;Due to high clarithromycin and quinolones resistance rates, we recommend the use of bismuth quadruple or non-bismuth concomitant quadruple therapy for H. pylori eradication in Tuzla Canton, Bosnia and Herzegovina.&amp;lt;\/p&amp;gt;<\/jats:p>","DOI":"10.17392\/1609-23","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T10:28:16Z","timestamp":1713695296000},"page":"163-168","source":"Crossref","is-referenced-by-count":1,"title":["Helicobacter pylori resistance to clarithromycin and quinolones in patients with dyspepsia in Tuzla Canton, Bosnia and Herzegovina"],"prefix":"10.17392","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-8987","authenticated-orcid":false,"given":"Ismar","family":"Hasuki\u0107","sequence":"first","affiliation":[{"name":"University Clinical Centre Tuzla","place":["Tuzla,Bosnia and Herzegovina"],"department":["Department of Gastroenterology and Hepatology"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nermin","family":"Salki\u0107","sequence":"additional","affiliation":[{"name":"University Clinical Centre Tuzla","place":["Tuzla,Bosnia and Herzegovina"],"department":["Department of Gastroenterology and Hepatology"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nijaz","family":"Tihi\u0107","sequence":"additional","affiliation":[{"name":"University Clinical Centre Tuzla","place":["Tuzla,Bosnia and Herzegovina"],"department":["Department of Microbiology"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ervin","family":"Alibegovi\u0107","sequence":"additional","affiliation":[{"name":"University Clinical Centre Tuzla","place":["Tuzla,Bosnia and Herzegovina"],"department":["Department of Gastroenterology and Hepatology"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0160efik","family":"Hasuki\u0107","sequence":"additional","affiliation":[{"name":"University Clinical Centre Tuzla","place":["Tuzla,Bosnia and Herzegovina"],"department":["Department of Surgery"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Jahi\u0107","sequence":"additional","affiliation":[{"name":"University Clinical Centre Tuzla","place":["Tuzla,Bosnia and Herzegovina"],"department":["Department of Invasive Cardiology"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"49509","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/antibiotics12020191","article-title":"Helicobacter pylori infection: current status and future prospects on diagnostic, therapeutic and control challenges","author":"AElbehiryA","year":"2023","unstructured":"Elbehiry A, Marzouk E, Aldubaib M, Abalkhail A, \nAnagreyyah S, Anajirih N, Almuzaini AM, Rawway \nM, Alfadhel A, Draz A, Abu-Okail A. Helicobacter \npylori infection: current status and future prospects \non diagnostic, therapeutic and control challenges. \nAntibiotics 2023; 12:191.","journal-title":"Antibiotics"},{"key":"ref2","first-page":"2022","article-title":"European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","author":"PMalfertheinerP","year":"2022","unstructured":"Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, \nLiou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, \nO'Morain C, Rugge M, Suerbaum S, Tilg H, Sugano \nK, El-Omar EM. European Helicobacter and Micro-\nbiota Study group. Management of Helicobacter \npylori infection: the Maastricht VI\/Florence consen-\nsus report. Gut 2022; 2022-327745.","journal-title":"Gut"},{"key":"ref3","first-page":"44","article-title":"Prevalence of Helicobacter pylori and its associated factors among healthy asymptomatic residents in the United Arab Emirates","author":"GKhoderG","year":"2019","unstructured":"Khoder G, Muhammad JS, Mahmoud I, Soliman \nSSM, Burucoa C. Prevalence of Helicobacter pylori \nand its associated factors among healthy asympto-\nmatic residents in the United Arab Emirates. Patho-\ngens 2019; 8:44.","journal-title":"Pathogens"},{"key":"ref4","article-title":"Schistosomes, Liver Flukes and Helicobacter pylori","year":"1994","unstructured":"Working-Group; World Health Organization, In-\nternational Agency for Research on Cancer, editor. \nSchistosomes, Liver Flukes and Helicobacter pylori. \nLyon, France: 1994."},{"key":"ref5","first-page":"1372","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization Regions","author":"ASavoldiA","year":"2018","unstructured":"Savoldi A, Carrara E, Graham DY, Conti M, \nTacconelli E. Prevalence of antibiotic resistance \nin Helicobacter pylori: a systematic review and \nmeta-analysis in World Health Organization Regi-\nons. Gastroenterology 2018; 155:1372-82.","journal-title":"Gastroenterology"},{"key":"ref6","first-page":"2255","article-title":"Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides","author":"\u00c9Kocsm\u00e1r\u00c9","year":"2021","unstructured":"Kocsm\u00e1r \u00c9, Buz\u00e1s GM, Szirtes I, Kocsm\u00e1r I, Kra-\nmer Z, Szij\u00e1rt\u00f3 A, Fadgyas-Freyler P, Sz\u00e9n\u00e1s K, Ru-\ngge M, Fassan M, Kiss A, Schaff Z, R\u00f6st G, Lotz G. \nPrimary and secondary clarithromycin resistance in \nHelicobacter pylori and mathematical modeling of \nthe role of macrolides. Nat Commun 2021; 12:2255.","journal-title":"Nat Commun"},{"key":"ref7","first-page":"53","article-title":"Genetic determinants and prediction of antibiotic resistance phenotypes in Helicobacter pylori","author":"FLauenerF","year":"2019","unstructured":"Lauener FN, Imkamp F, Lehours P, Buissonni\u00e8re \nA, Benejat L, Zbinden R, Keller PM, Wagner K. \nGenetic determinants and prediction of antibiotic \nresistance phenotypes in Helicobacter pylori. J Clin \nMed 2019; 8:53.","journal-title":"J Clin Med"},{"key":"ref8","first-page":"168","article-title":"Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance","author":"YHuY","year":"2017","unstructured":"Hu Y, Zhu Y , Lu NH. Novel and effective therape-\nutic regimens for Helicobacter pylori in an era of \nincreasing antibiotic resistance. Front Cell Infect \nMicrobiol 2017; 7:168.","journal-title":"Front Cell Infect Microbiol"},{"key":"ref9","first-page":"226","article-title":"Geno Type HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones","author":"NPastukhN","year":"2017","unstructured":"Pastukh N, Binyamin D, On A, Paritsky M, Peretz A. \nGeno Type HelicoDR test in comparison with histo-\nlogy and culture for Helicobacter pylori detection and \nidentification of resistance mutations to clarithromycin \nand fluoroquinolones. Helicobacter 2017; 22:226.","journal-title":"Helicobacter"},{"key":"ref10","first-page":"101","article-title":"Sensitivity of Helicobacter pylori detection by Giemsa staining is poor in comparison with immunohistochemistry and fluorescent in situ hybridization and strongly depends on inflammatory activity","author":"\u00c9Kocsm\u00e1r\u00c9","year":"2017","unstructured":"Kocsm\u00e1r \u00c9, Szirtes I, Kramer Z, Szij\u00e1rt\u00f3 A, Bene L, \nBuz\u00e1s GM, Kenessey I, Bronsert P, Csanadi A, Lutz \nL, Werner M, Wellner UF, Kiss A, Schaff Z, Lotz \nG. Sensitivity of Helicobacter pylori detection by \nGiemsa staining is poor in comparison with immu-\nnohistochemistry and fluorescent in situ hybridiza-\ntion and strongly depends on inflammatory activity. \nHelicobacter 2017; 22:101-11.","journal-title":"Helicobacter"},{"key":"ref11","first-page":"495","article-title":"Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis","author":"TRokkasT","year":"2021","unstructured":"Rokkas, T, Gisbert JP, Malfertheiner P, Niv Y, \nGasbarrini A, Leja M, Megraud F, O'Morain C, \nGraham DY. Comparative effectiveness of multiple \ndifferent first-line treatment regimens for Helicobac-\nter pylori infection: a network meta-analysis. Ga-\nstroenterology 2021; 161: 495-507.","journal-title":"Gastroenterology"},{"key":"ref12","first-page":"685","article-title":"Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial","author":"GHauserG","year":"2015","unstructured":"Hauser G, Salkic N, Vukelic K, Jajac Knez A, Sti-\nmac D. Probiotics for standard triple Helicobacter \npylori eradication: a randomized, double-blind, pla-\ncebo-controlled trial. Medicine (Baltimore) 2015; \n94: 685.","journal-title":"Medicine (Baltimore)"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"8168","DOI":"10.3748\/wjg.v19.i45.8168","article-title":"How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?","author":"EIerardiE","year":"2013","unstructured":"Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi \nM. How antibiotic resistances could change Heli-\ncobacter pylori treatment: A matter of geography? \nWorld J Gastroenterol 2013; 19: 8168-80.","journal-title":"World J Gastroenterol"},{"key":"ref14","first-page":"51","article-title":"Realtime PCR detection of Helicobacter pylori clarithromycin resistance in Thrace","author":"AKarvelasA","year":"2021","unstructured":"Karvelas A, Martinez-Gonzalez B, Papadopoulos \nVP, Panopoulou M, Sgouras D, Mimidis K. Real-\ntime PCR detection of Helicobacter pylori clarit-\nhromycin resistance in Thrace, Greece. Hippokratia \n2021; 25:51-55.","journal-title":"Hippokratia"},{"key":"ref15","first-page":"1445","article-title":"Detection of Helicobacter pylori by invasive tests in adult dyspeptic patients and antibacterial resistance to six antibiotics, including rifampicin in Turkey. Is clarithromycin resistance rate decreasing?","author":"MAkarM","year":"2021","unstructured":"Akar M, Ayd\u0131n F, Kayman T, Abay S, Karakaya E. \nDetection of Helicobacter pylori by invasive tests in \nadult dyspeptic patients and antibacterial resistance \nto six antibiotics, including rifampicin in Turkey. \nIs clarithromycin resistance rate decreasing? Turk J \nMed Sci 2021;51:1445-64.","journal-title":"Turk J Med Sci"},{"key":"ref16","first-page":"41","article-title":"Investigation of multidrug-resistant Helicobacter pylori in pediatric patients: a Bulgarian study and literature data","author":"LBoyanovaL","year":"2022","unstructured":"Boyanova L, Hadzhiyski P, Markovska R, Gergova \nR. Investigation of multidrug-resistant Helicobacter \npylori in pediatric patients: a Bulgarian study and li-\nterature data. Acta Microbiol Immunol Hung 2022; \n69:41-5.","journal-title":"Acta Microbiol Immunol Hung"},{"key":"ref17","first-page":"377","article-title":"Current trends in the management of Helicobacter pylori infection in Serbia: preliminary results from the European registry on H. pylori management (Hp-EuReg)","author":"VMilivojevicV","year":"2022","unstructured":"Milivojevic V, Babic I, Kekic D, Rankovic I, Sagdati \nS, Panic N, Sekulic Spasic I, Krstic M, Milosavljevic \nT, Moreira L, Perez Nyssen O, M\u00e9graud F, O' Mo-\nrain C, Gisbert J. Current trends in the management \nof Helicobacter pylori infection in Serbia: prelimi-\nnary results from the European registry on H. pylori \nmanagement (Hp-EuReg). Dig Dis 2022 ; 40:377-86","journal-title":"Dig Dis"},{"key":"ref18","first-page":"182","article-title":"Time trends of primary antibiotic resistance of Helicobacter pylori isolates in Southern Croatia","author":"ATonkicA","year":"2012","unstructured":"Tonkic A, Tonkic M, Brnic D, Novak A, Puljiz Z, \nSimunic M. Time trends of primary antibiotic re-\nsistance of Helicobacter pylori isolates in Southern \nCroatia. J Chemother 2012; 24:182-4.","journal-title":"J Chemother"},{"key":"ref19","first-page":"1815","article-title":"European Helicobacter pylori antimicrobial susceptibility testing Working Group. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community","author":"FMegraudF","year":"2021","unstructured":"Megraud F, Bruyndonckx R, Coenen S, Wittkop L, \nHuang TD, Hoebeke M, B\u00e9n\u00e9jat L, Lehours P, Goo-\nssens H, Glupczynski Y. European Helicobacter pylo-\nri antimicrobial susceptibility testing Working Group. \nHelicobacter pylori resistance to antibiotics in Europe \nin 2018 and its relationship to antibiotic consumption \nin the community. Gut 2021; 70:1815-22.","journal-title":"Gut"},{"key":"ref20","first-page":"524","article-title":"Antimicrobial susceptibility testing for Helicobacter pylori is now widely available: when, how, why","author":"DGrahamD","year":"2022","unstructured":"Graham DY, Moss SF. Antimicrobial susceptibility \ntesting for Helicobacter pylori is now widely ava-\nilable: when, how, why. Am J Gastroenterol 2022; \n117:524-8.","journal-title":"Am J Gastroenterol"}],"container-title":["Medicinski Glasnik"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/medicinskiglasnik.ba\/article\/31\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicinskiglasnik.ba\/article\/31\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:45:07Z","timestamp":1775468707000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicinskiglasnik.ba\/article\/id\/432\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12,1]]},"published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.17392\/1609-23","archive":["Internet Archive"],"relation":{},"ISSN":["1840-0132","1840-0132"],"issn-type":[{"value":"1840-0132","type":"electronic"},{"value":"1840-0132","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}